Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial
Background. This partially blinded, randomized, phase 2a C210 study evaluated the antiviral activity of telaprevir-based regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection. Methods. Twenty-four patients received telaprevir 750 mg every 8 hours for 15 days (T; n = 8), telaprevir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 days (TPR; n = 8), or Peg-IFN/RBV plus placebo for 15 days (PR; n = 8), followed by Peg-IFN/RBV for 46 or 48 weeks. The primary objective was to assess the effect of telaprevir on HCV RNA levels. Results. HCV RNA levels decreased slightly with T and PR; TPR produced substantial, rapid declines. On day 15, median reductions in the HCV RNA load from baseline were –0.77, –4.32, and –1.58 log₁₀ IU/mL for T, TPR, and PR, respectively, and 0 patients in the T group, 1 in the TPR group, and 0 in the PR group had undetectable HCV RNA. Five of 8 patients who received telaprevir monotherapy had viral breakthrough within 15 days of treatment. Adverse event incidence was similar across treatments and comparable with the incidences from previous clinical trials. One patient (in T group) had a serious adverse event (considered unrelated to telaprevir) that led to treatment discontinuation. Conclusions. Telaprevir with Peg-IFN/RBV had greater activity than Peg-IFN/RBV treatment or telaprevir monotherapy against HCV genotype 4. Telaprevir was generally safe and well tolerated. Further investigation of telaprevir combination therapy in patients with HCV genotype 4 infection is warranted. Clinical Trials Registration. NCT00580801..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:208 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Benhamou, Yves [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biological sciences |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
JST124182631 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | JST124182631 | ||
003 | DE-627 | ||
005 | 20230929093713.0 | ||
007 | cr uuu---uuuuu | ||
008 | 190102s2013 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)JST124182631 | ||
035 | |a (JST)42580440 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Benhamou, Yves |e verfasserin |4 aut | |
245 | 1 | 0 | |a Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background. This partially blinded, randomized, phase 2a C210 study evaluated the antiviral activity of telaprevir-based regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection. Methods. Twenty-four patients received telaprevir 750 mg every 8 hours for 15 days (T; n = 8), telaprevir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 days (TPR; n = 8), or Peg-IFN/RBV plus placebo for 15 days (PR; n = 8), followed by Peg-IFN/RBV for 46 or 48 weeks. The primary objective was to assess the effect of telaprevir on HCV RNA levels. Results. HCV RNA levels decreased slightly with T and PR; TPR produced substantial, rapid declines. On day 15, median reductions in the HCV RNA load from baseline were –0.77, –4.32, and –1.58 log₁₀ IU/mL for T, TPR, and PR, respectively, and 0 patients in the T group, 1 in the TPR group, and 0 in the PR group had undetectable HCV RNA. Five of 8 patients who received telaprevir monotherapy had viral breakthrough within 15 days of treatment. Adverse event incidence was similar across treatments and comparable with the incidences from previous clinical trials. One patient (in T group) had a serious adverse event (considered unrelated to telaprevir) that led to treatment discontinuation. Conclusions. Telaprevir with Peg-IFN/RBV had greater activity than Peg-IFN/RBV treatment or telaprevir monotherapy against HCV genotype 4. Telaprevir was generally safe and well tolerated. Further investigation of telaprevir combination therapy in patients with HCV genotype 4 infection is warranted. Clinical Trials Registration. NCT00580801. | ||
540 | |a Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America | ||
650 | 4 | |a Physical sciences |x Chemistry |x Chemical compounds |x Chemicals |x Acids |x Nucleic acids |x RNA | |
650 | 4 | |a Biological sciences |x Biology |x Genetics |x Genotypes | |
650 | 4 | |a Biological sciences |x Biology |x Microbiology |x Microorganisms |x Viruses | |
650 | 4 | |a Health sciences |x Medical conditions |x Infections | |
650 | 4 | |a Health sciences |x Medical conditions |x Diseases |x Infectious diseases |x Hepatitis | |
650 | 4 | |a Social sciences |x Psychology |x Clinical psychology |x Psychotherapy |x Psychotherapeutic techniques |x Group psychotherapy |x Encounter groups | |
650 | 4 | |a Health sciences |x Medical sciences |x Pharmacology |x Clinical pharmacology |x Pharmacokinetics | |
650 | 4 | |a Biological sciences |x Biochemistry |x Biomolecules |x Cytokines |x Interferons | |
650 | 4 | |a Health sciences |x Medical treatment |x Investigational therapies | |
650 | 4 | |a Health sciences |x Medical sciences |x Pharmaceutics |x Pharmaceutical preparations |x Medications |x Antiinfectives |x Antivirals |x MAJOR ARTICLES AND BRIEF REPORTS |x VIRUSES | |
655 | 4 | |a research-article | |
700 | 1 | |a Moussalli, Joseph |e verfasserin |4 aut | |
700 | 1 | |a Ratziu, Vlad |e verfasserin |4 aut | |
700 | 1 | |a Lebray, Pascal |e verfasserin |4 aut | |
700 | 1 | |a De Backer, Katrien |e verfasserin |4 aut | |
700 | 1 | |a De Meyer, Sandra |e verfasserin |4 aut | |
700 | 1 | |a Ghys, Anne |e verfasserin |4 aut | |
700 | 1 | |a Luo, Donghan |e verfasserin |4 aut | |
700 | 1 | |a Picchio, Gaston R. |e verfasserin |4 aut | |
700 | 1 | |a Beumont, Maria |e verfasserin |4 aut | |
773 | 1 | 8 | |g volume:208 |g year:2013 |g number:6 |g pages:1000-1007 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jit274 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_JST | ||
951 | |a AR | ||
952 | |d 208 |j 2013 |e 6 |h 1000-1007 |